Li Jiaxi, Zhang Xiaowen, Li Lintong, Zhu Qiaoling, Ge Weihong, Ji Cheng
Department of Pharmacy, China Pharmaceutical University Nanjing Drum Tower Hospital, Nanjing, China.
Nanjing Medical Center for Clinical Pharmacy, Nanjing, China.
Int J Endocrinol. 2023 Apr 10;2023:9935195. doi: 10.1155/2023/9935195. eCollection 2023.
To study the risk factors for granulocytopenia caused by antithyroid drugs.
Patients who were diagnosed with Graves' hyperthyroidism and regularly treated with antithyroid drugs (ATDs) from January 2010 to July 2022 at Nanjing Drum Tower Hospital, aged >18 years, were selected for general information and laboratory tests and divided into two groups according to the occurrence of granulocytopenia. Independent risk factors for the development of granulocytopenia in patients treated with ATDs were analyzed using one-way and multiway logistic regression analyses, and the predictive value of each index was evaluated using the receiver operating characteristic (ROC) curve and the area under the curve (AUC).
A total of 818 patients were enrolled, of which 95 developed granulocytopenia. Univariate analysis revealed that sex, white blood cell (WBC) counts, neutrophil-to-lymphocyte ratio (NLR), glutamic-pyruvic transaminase (ALT), aspartate transaminase (AST), free triiodothyronine (FT3), free thyroxine (FT4), and thyroid stimulating hormone (TSH) before medication were risk factors for ATD-induced granulocytopenia ( < 0.05). The abovementioned indicators were taken as independent variables, and multivariate logistic regression analysis showed that female sex, higher ALT levels before medication, and lower NLR and WBC levels were independent risk factors for granulocytopenia using ATDs ( < 0.05). ROC curve analysis showed that sex, NLR, ALT, and WBC count had significant predictive values ( < 0.05), and NLR and WBC count had higher predictive values (AUC = 0.916 and 0.700, respectively).
Sex, NLR, ALT, and WBC were the main risk factors for granulocytopenia in patients with ATD.
研究抗甲状腺药物所致粒细胞减少症的危险因素。
选取2010年1月至2022年7月在南京鼓楼医院确诊为Graves病甲亢并接受抗甲状腺药物(ATD)正规治疗、年龄>18岁的患者,收集其一般资料及实验室检查结果,并根据是否发生粒细胞减少症分为两组。采用单因素和多因素logistic回归分析ATD治疗患者发生粒细胞减少症的独立危险因素,并用受试者工作特征(ROC)曲线及曲线下面积(AUC)评估各指标的预测价值。
共纳入818例患者,其中95例发生粒细胞减少症。单因素分析显示,性别、白细胞(WBC)计数、中性粒细胞与淋巴细胞比值(NLR)、谷丙转氨酶(ALT)、谷草转氨酶(AST)、用药前游离三碘甲状腺原氨酸(FT3)、游离甲状腺素(FT4)及促甲状腺激素(TSH)是ATD所致粒细胞减少症的危险因素(P<0.05)。以上述指标为自变量进行多因素logistic回归分析,结果显示女性、用药前ALT水平较高、NLR及WBC水平较低是使用ATD发生粒细胞减少症的独立危险因素(P<0.05)。ROC曲线分析显示,性别、NLR、ALT及WBC计数具有显著预测价值(P<0.05),其中NLR和WBC计数预测价值较高(AUC分别为0.916和0.700)。
性别、NLR、ALT及WBC是ATD治疗患者发生粒细胞减少症的主要危险因素。